5-fluoruracil, doxorubicin and ciclophosphamyde (FAC) followed by docetaxel (TXT) as adjuvant chemotherapy in node positive early breast cancer: Toxicity and safety

被引：0
|
作者：
Ratti, R. [1 ]
Coccorullo, Z. [1 ]
Guarneri, D. [1 ]
Addamo, G. [1 ]
Colloca, G. [1 ]
Venturino, A. [1 ]
Campora, E. [1 ]
机构：
[1] Stabilimento Osped Sanremo, San Remo, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study
    Cardoso, F
    Ferreira, AF
    Crown, J
    Dolci, S
    Paesmans, M
    Riva, A
    Di Leo, A
    Piccart, MJ
    [J]. ANTICANCER RESEARCH, 2001, 21 (1B) : 789 - 795
  • [2] A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Rapoport, B. L.
    Moodley, S. D.
    Jacobs, C.
    Pienaar, R.
    Fourie, S.
    Szpak, W. M.
    [J]. BREAST, 2007, 16 : S64 - S64
  • [3] Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer.
    Lara, R
    Mayordomo, JI
    Modolell, A
    Burillo, M
    Sanz, J
    Murillo, L
    Janariz, J
    Perez, V
    Andres, R
    Tres, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 72S - 72S
  • [4] Safety analysis of docetaxel (T) and doxorubicin (A) followed by sequential capecitabine (X) as adjuvant chemotherapy of patients with node-positive operable breast cancer (BC).
    Mayordomo, JI
    Madroñal, C
    Garcia-Lopez, MJ
    Burillo, MA
    Perez, V
    Janariz, J
    Murillo, L
    Andres, R
    Lara, R
    Lambea, J
    Sanz, IAJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 80S - 80S
  • [5] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    [J]. JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [6] OBSERVED TOXICITIES DURING THE ADJUVANT TREATMENT WITH DOCETAXEL FOLLOWING FAC CHEMOTHERAPY IN THE WOMEN WITH NODE POSITIVE EARLY BREAST CANCER - SINGLE INSTITUTION EXPERIENCE
    Bozovic-Spasojevic, I.
    Neskovic-Konstatinovic, Z.
    Susnjar, S.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 32 - 32
  • [7] Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy for node-positive breast cancer
    Suh, Y.
    Oh, S.
    Song, B.
    Jung, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
    Mirzaei, Hamid Reza
    Rasekh, Parisa Sabet
    Nasrollahi, Fatemeh
    Rasekh, Parto Sabet
    Tirabad, Zahra Akbari
    RezaMoein, Hamid
    Pour, Taban Ghaffari
    Hajian, Parastoo
    [J]. INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [9] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [10] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
12345